## IDXX: IDEXX Laboratories, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.9% below STRENGTH zone (4.0-10.0%); PEG 4.16 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($662.75)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. BofA Securities Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Maintains Target Price $790**
- Source: 富途牛牛 | 20251215T180816 | Neutral | Relevance: 100%
- BofA Securities analyst Michael Ryskin has maintained a "Hold" rating for IDEXX Laboratories Inc (IDXX.US), retaining a target price of $790. According to TipRanks data, Ryskin has a 56.4% success rate and an average return of 4.2% over the past year. This report provides an overview of the analyst's recommendation and TipRanks' methodology for assessing analyst performance.

**2. 1,735 Shares in IDEXX Laboratories, Inc. $IDXX Bought by Stance Capital LLC**
- Source: MarketBeat | 20251215T115828 | Bullish | Relevance: 100%
- Stance Capital LLC recently acquired 1,735 shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) stock, valued at approximately $931,000, as disclosed in their latest SEC filing. This acquisition is part of a broader trend of institutional investors adjusting their positions in IDEXX, with the stock currently trading down 0.5%. The company reported strong financial results in its last earnings call, beating analyst estimates, and has received a "Moderate Buy" consensus rating from analysts, with an average target price of $763.50.

**3. With EPS Growth And More, IDEXX Laboratories (NASDAQ:IDXX) Makes An Interesting Case**
- Source: 富途牛牛 | 20251214T200820 | Bullish | Relevance: 100%
- IDEXX Laboratories (NASDAQ:IDXX) presents an interesting investment case due to its consistent EPS growth of 17% annually over three years and 8.4% revenue growth to US$4.2 billion. Insiders also hold a significant stake worth US$552 million, representing 1.0% of the company, which aligns their interests with shareholders. This combination of strong financial performance and insider confidence suggests IDEXX Laboratories warrants further investigation by investors.

**4. Corient Private Wealth LLC Sells 3,030 Shares of IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251216T100558 | Somewhat-Bullish | Relevance: 99%
- Corient Private Wealth LLC reduced its stake in IDEXX Laboratories (NASDAQ:IDXX) by 2.5%, selling 3,030 shares, though it still holds 117,474 shares valued at $63 million. Despite this sale, institutional ownership remains high at 87.84% due to other large investors significantly increasing their holdings. IDEXX Laboratories reported a strong earnings beat and positive revenue, with a "Moderate Buy" consensus analyst rating and a price target of $763.50.

**5. IDEXX Laboratories, Inc. $IDXX Position Increased by Curi Capital LLC**
- Source: MarketBeat | 20251213T110806 | Bullish | Relevance: 98%
- Curi Capital LLC significantly increased its stake in IDEXX Laboratories (NASDAQ:IDXX) by 232.3% in Q2, bringing its total holdings to 31,645 shares valued at approximately $16.97 million. Institutional investors now own about 87.84% of the company's stock, reflecting strong institutional confidence. Analysts maintain a "Moderate Buy" consensus rating for IDEXX, with price targets ranging up to $850, following the company's Q3 earnings beat and positive FY2025 guidance.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $850 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($2.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+0.9%)
- Blackrock Inc.: 10.3% (-2.0%)
- State Street Corpora: 4.4% (-1.0%)
- Fundsmith LLP: 3.3% (-1.1%)
- Geode Capital Manage: 3.1% (+1.4%)

### Key Risks

1. Valuation stretched: PEG 4.2x requires aggressive growth execution.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.16 signals overvaluation risk, limited margin of safety. Forward P/E 48.6x stretched relative to 12% growth. Quality metrics strong (ROE 65%, ROA 24%, margin 25%). Insider buying signal ($2.1M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $56.0B |
| Beta | 1.67 |
| 52W Range | $356.14 - $769.98 |
| Short Interest | 3.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.16 |
| Forward P/E | 48.6 |
| Current P/E | 54.3 |
| YoY Growth | 11.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -4.5% to -1.9% (+2.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.9pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.2%) - potential reversal signal. Underperforming sector by 3.3pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.24x) but short-term weakness (below SMA20). MACD histogram bearish (-5.76), momentum weakening. RSI neutral at 48. OFD pattern: -MLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.90% (CS: 21) | Neutral |
| RSI_14 | 47.9 | Neutral |
| MACD Histogram | -5.76 | Bearish |
| vs SMA20 | 0.979x | Below |
| vs SMA50 | 1.027x | Above |
| vs SMA200 | 1.236x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $700.55
- **Stop Loss:** $662.75 (5.4% risk)
- **Target:** $738.35 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 31
- **Position Value:** $21,717.05
- **Portfolio %:** 21.72%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-03 (Est: $2.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.14 | $3.40 | +8.3% |
| 2025Q2 | $3.30 | $3.63 | +10.0% |
| 2025Q1 | $2.85 | $2.96 | +3.9% |
| 2024Q4 | $2.40 | $2.62 | +9.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*